{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:05:40Z","timestamp":1789146340061,"version":"build-2803163510"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009101","name":"Department of Education of Henan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010950","name":"Department of Science and Technology of Henan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.intimp.2026.117165","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:49:43Z","timestamp":1784742583000},"page":"117165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting antibody-inaccessible immune resistance with small-molecule immunotherapy"],"prefix":"10.1016","volume":"187","author":[{"given":"Jin-Man","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Jie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.intimp.2026.117165_bb0005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2026.117165_bb0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"issue":"26","key":"10.1016\/j.intimp.2026.117165_bb0015","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.intimp.2026.117165_bb0020","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.117165_bb0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/mutage\/geu073","article-title":"Paradigm shift in oncology: targeting the immune system rather than cancer cells","volume":"30","author":"Shekarian","year":"2015","journal-title":"Mutagenesis"},{"issue":"6230","key":"10.1016\/j.intimp.2026.117165_bb0030","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.intimp.2026.117165_bb0035","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3389\/fimmu.2020.00933","article-title":"Editorial: targeting the tumor microenvironment for a more effective and efficient Cancer immunotherapy","volume":"11","author":"Chouaib","year":"2020","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2026.117165_bb0040","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117165_bb0045","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nri1457","article-title":"IDO expression by dendritic cells: tolerance and tryptophan catabolism","volume":"4","author":"Mellor","year":"2004","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.117165_bb0050","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.intimp.2026.117165_bb0055","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","article-title":"The emerging role of epigenetic therapeutics in immuno-oncology","volume":"17","author":"Topper","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117165_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2026.117165_bb0065","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.intimp.2026.117165_bb0070","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in Cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.intimp.2026.117165_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189170","article-title":"Small-molecule in cancer immunotherapy: revolutionizing cancer treatment with transformative, game-changing breakthroughs","volume":"1879","author":"Chattopadhyay","year":"2024","journal-title":"Biochimica et Biophysica acta (BBA) - reviews on Cancer"},{"key":"10.1016\/j.intimp.2026.117165_bb0080","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"7629","key":"10.1016\/j.intimp.2026.117165_bb0085","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0090","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2026.117165_bb0095","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell Metab."},{"issue":"10","key":"10.1016\/j.intimp.2026.117165_bb0100","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3390\/cells9102308","article-title":"Cancer metabolism: phenotype, signaling and therapeutic targets","volume":"9","author":"Park","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2026.117165_bb0105","doi-asserted-by":"crossref","first-page":"1440269","DOI":"10.3389\/fimmu.2024.1440269","article-title":"Targeting amino acid-metabolizing enzymes for cancer immunotherapy","volume":"15","author":"Grobben","year":"2024","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117165_bb0110","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1172\/JCI131859","article-title":"Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells","volume":"130","author":"Oh","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.intimp.2026.117165_bb0115","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.trecan.2021.04.003","article-title":"Enhancing the efficacy of glutamine metabolism inhibitors in Cancer therapy","volume":"7","author":"Yang","year":"2021","journal-title":"Trends Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2026.117165_bb0120","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s12276-023-00971-9","article-title":"Targeting glutamine metabolism as a therapeutic strategy for cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"4","key":"10.1016\/j.intimp.2026.117165_bb0125","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","article-title":"Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast Cancer","volume":"13","author":"Gross","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.intimp.2026.117165_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113295","article-title":"KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance","volume":"42","author":"Zavitsanou","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2026.117165_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.889826","article-title":"LKB1: can we target an hidden target? Focus on NSCLC","volume":"12","author":"Ndembe","year":"2022","journal-title":"Front. Oncol."},{"issue":"13","key":"10.1016\/j.intimp.2026.117165_bb0140","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1158\/0008-5472.CAN-18-3527","article-title":"LKB1 and KEAP1\/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma","volume":"79","author":"Galan-Cobo","year":"2019","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.117165_bb0145","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/1535-7163.MCT-20-0430","article-title":"The glutaminase inhibitor CB-839 (Telaglenastat) enhances the antimelanoma activity of T-cell\u2013mediated immunotherapies","volume":"20","author":"Varghese","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.intimp.2026.117165_bb0150","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.tips.2015.03.006","article-title":"Arginase: an old enzyme with new tricks","volume":"36","author":"Caldwell","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2026.117165_bb0155","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.it.2020.04.004","article-title":"Opportunities for small molecules in Cancer immunotherapy","volume":"41","author":"van der Zanden","year":"2020","journal-title":"Trends Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117165_bb0160","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1476-5381.2009.00291.x","article-title":"Arginase: an emerging key player in the mammalian immune system","volume":"158","author":"Munder","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2026.117165_bb0165","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.drudis.2018.01.046","article-title":"Research of novel anticancer agents targeting arginase inhibition","volume":"23","author":"Pham","year":"2018","journal-title":"Drug Discov. Today"},{"issue":"24","key":"10.1016\/j.intimp.2026.117165_bb0170","doi-asserted-by":"crossref","first-page":"21123","DOI":"10.1074\/jbc.M110675200","article-title":"Regulation of T cell receptor CD3\u03b6 chain expression byl-arginine","volume":"277","author":"Rodriguez","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.intimp.2026.117165_bb0175","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2006-06-031856","article-title":"L-arginine availability regulates T-lymphocyte cell-cycle progression","volume":"109","author":"Rodriguez","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.intimp.2026.117165_bb0180","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/intimm\/dxs004","article-title":"Arginine deficiency leads to impaired cofilin dephosphorylation in activated human T lymphocytes","volume":"24","author":"Feldmeyer","year":"2012","journal-title":"Int. Immunol."},{"key":"10.1016\/j.intimp.2026.117165_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112840","article-title":"Arginase: an emerging and promising therapeutic target for cancer treatment","volume":"149","author":"Niu","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0190","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","article-title":"Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment","volume":"5","author":"Steggerda","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0195","doi-asserted-by":"crossref","DOI":"10.1136\/bmjonc-2023-000249","article-title":"First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours","volume":"3","author":"Naing","year":"2024","journal-title":"BMJ Oncology."},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0200","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol. Cancer"},{"issue":"13","key":"10.1016\/j.intimp.2026.117165_bb0205","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108130","article-title":"ATP and cancer immunosurveillance","volume":"40","author":"Kepp","year":"2021","journal-title":"EMBO J."},{"key":"10.1016\/j.intimp.2026.117165_bb0210","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-med-060619-023155","article-title":"Inhibition of the adenosine pathway to potentiate Cancer immunotherapy: potential for combinatorial approaches","volume":"72","author":"Thompson","year":"2021","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0215","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4161\/onci.1.1.18068","article-title":"CD73 promotes tumor growth and metastasis","volume":"1","author":"Zhang","year":"2014","journal-title":"OncoImmunology"},{"issue":"15","key":"10.1016\/j.intimp.2026.117165_bb0220","doi-asserted-by":"crossref","first-page":"8068","DOI":"10.3390\/ijms22158068","article-title":"CD39 regulation and functions in T cells","volume":"22","author":"Timperi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117165_bb0225","doi-asserted-by":"crossref","first-page":"1297175","DOI":"10.3389\/fimmu.2023.1297175","article-title":"Small molecule inhibitors for cancer immunotherapy and associated biomarkers - the current status","volume":"14","author":"Schlicher","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117165_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2024.110774","article-title":"Targeting the adenosine signaling pathway in macrophages for cancer immunotherapy","volume":"85","author":"Yang","year":"2024","journal-title":"Hum. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0235","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","article-title":"Targeting adenosine for cancer immunotherapy","volume":"6","author":"Leone","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2026.117165_bb0240","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/1535-7163.MCT-21-0802","article-title":"Targeting CD73 with AB680 (Quemliclustat), a novel and potent small-molecule CD73 inhibitor, restores immune functionality and facilitates antitumor immunity","volume":"21","author":"Piovesan","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"33","key":"10.1016\/j.intimp.2026.117165_bb0245","article-title":"Tumor microenvironment responsive CD8(+) T cells and myeloid-derived suppressor cells to trigger CD73 inhibitor AB680-based synergistic therapy for pancreatic Cancer","volume":"10","author":"Chen","year":"2023","journal-title":"Adv Sci (Weinh)."},{"issue":"7","key":"10.1016\/j.intimp.2026.117165_bb0250","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s00432-024-05869-1","article-title":"Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma","volume":"150","author":"Sun","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2026.117165_bb0255","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/s41416-022-02013-z","article-title":"Impact of the selective A2AR and A2BR dual antagonist AB928\/etrumadenant on CAR T cell function","volume":"127","author":"Seifert","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2026.117165_bb0260","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10637-018-0706-6","article-title":"Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers","volume":"37","author":"Seitz","year":"2019","journal-title":"Investig. New Drugs"},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0265","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-024-03817-z","article-title":"Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells","volume":"74","author":"Khaliulin","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.intimp.2026.117165_bb0270","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/2326-6066.CIR-18-0056","article-title":"A2AR antagonism with CPI-444 induces antitumor responses and augments efficacy to anti\u2013PD-(L)1 and anti\u2013CTLA-4 in preclinical models","volume":"6","author":"Willingham","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2026.117165_bb0275","doi-asserted-by":"crossref","first-page":"vi124","DOI":"10.1093\/annonc\/mdw368.32","article-title":"Biomarker and clinical activity of CPI-444, a novel small molecule inhibitor of A2A receptor (A2AR), in a Ph1b study in advanced cancers","volume":"27","author":"McCaffery","year":"2016","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.intimp.2026.117165_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810134","article-title":"Kynurenine pathway of tryptophan metabolism in migraine and functional gastrointestinal disorders","volume":"22","author":"Fila","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117165_bb0285","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.placenta.2019.04.007","article-title":"The kynurenine pathway; a new target for treating maternal features of preeclampsia?","volume":"84","author":"Worton","year":"2019","journal-title":"Placenta"},{"issue":"5","key":"10.1016\/j.intimp.2026.117165_bb0290","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.cell.2020.07.038","article-title":"IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression","volume":"182","author":"Sadik","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.intimp.2026.117165_bb0295","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11060-014-1687-8","article-title":"The role of IDO in brain tumor immunotherapy","volume":"123","author":"Zhai","year":"2014","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.intimp.2026.117165_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636081","article-title":"Tryptophan: a rheostat of Cancer immune escape mediated by immunosuppressive enzymes IDO1 and TDO","volume":"12","author":"Kim","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117165_bb0305","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.it.2012.10.001","article-title":"Indoleamine 2,3 dioxygenase and metabolic control of immune responses","volume":"34","author":"Munn","year":"2013","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0310","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-021-01080-8","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy","volume":"14","author":"Tang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"17","key":"10.1016\/j.intimp.2026.117165_bb0315","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","article-title":"Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity","volume":"115","author":"Liu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117165_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102461","article-title":"Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy","volume":"110","author":"Fujiwara","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2026.117165_bb0325","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1021\/acsmedchemlett.2c00525","article-title":"Inhibitors of interleukin 4 induced protein 1 (IL4I1) as potential treatment for Cancer","volume":"14","author":"Abdel-Magid","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0330","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41392-021-00529-z","article-title":"IL4I1-driven AHR signature: a new avenue for cancer therapy","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0335","doi-asserted-by":"crossref","first-page":"1924500","DOI":"10.1080\/2162402X.2021.1924500","article-title":"What role for AHR activation in IL4I1-mediated immunosuppression\u202f?","volume":"10","author":"Castellano","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.intimp.2026.117165_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103463","article-title":"Identification of inhibitors of the immunosuppressive enzyme IL4I1","volume":"94","author":"Presset","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"6","key":"10.1016\/j.intimp.2026.117165_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007362","article-title":"Cancer epigenetics: moving forward","volume":"14","author":"Nebbioso","year":"2018","journal-title":"PLoS Genet."},{"issue":"11","key":"10.1016\/j.intimp.2026.117165_bb0350","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/cac2.12374","article-title":"Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities","volume":"42","author":"Ge","year":"2022","journal-title":"Cancer Commun. (Lond.)"},{"issue":"4","key":"10.1016\/j.intimp.2026.117165_bb0355","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019521","article-title":"Histone modifications and Cancer","volume":"8","author":"Audia","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0360","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","article-title":"Epigenetic modulation of antitumor immunity for improved cancer immunotherapy","volume":"20","author":"Dai","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.117165_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107652","article-title":"Targeting DNA methyltransferases for cancer therapy","volume":"151","author":"Wang","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"23","key":"10.1016\/j.intimp.2026.117165_bb0370","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.3760\/cma.j.issn.0366-6999.20130526","article-title":"Demethylating agent decitabine induces autologous cancer testis antigen specific cytotoxic T lymphocytes in vivo","volume":"126","author":"Zhou","year":"2013","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.intimp.2026.117165_bb0375","doi-asserted-by":"crossref","first-page":"10903","DOI":"10.2147\/OTT.S217767","article-title":"<p>DNA methyltransferase inhibitors: catalysts for antitumour immune responses<\/p>","volume":"12","author":"Dan","year":"2019","journal-title":"Onco. Targets Ther."},{"issue":"3","key":"10.1016\/j.intimp.2026.117165_bb0380","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1586\/1744666X.2015.1002397","article-title":"Decitabine: a promising epi-immunotherapeutic agent in solid tumors","volume":"11","author":"Li","year":"2015","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2026.117165_bb0385","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/17474086.2017.1346470","article-title":"Immunological effects of hypomethylating agents","volume":"10","author":"Lindblad","year":"2017","journal-title":"Expert Rev. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0390","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12967-023-04073-y","article-title":"Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy","volume":"21","author":"Taib","year":"2023","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.intimp.2026.117165_bb0395","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41423-018-0026-y","article-title":"Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment","volume":"16","author":"Yu","year":"2018","journal-title":"Cell. Mol. Immunol."},{"issue":"17","key":"10.1016\/j.intimp.2026.117165_bb0400","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood-2014-10-607648","article-title":"Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia","volume":"125","author":"Ranganathan","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0405","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.tranon.2019.10.001","article-title":"Targeting tumor microenvironment by small-molecule inhibitors","volume":"13","author":"Zhong","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.intimp.2026.117165_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116129","article-title":"HDAC-targeting epigenetic modulators for cancer immunotherapy","volume":"265","author":"Cheng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.intimp.2026.117165_bb0415","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/2326-6066.CIR-18-0070","article-title":"Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint responsive Tumors by reprogramming tumor-infiltrating MDSCs","volume":"6","author":"Christmas","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"17","key":"10.1016\/j.intimp.2026.117165_bb0420","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","article-title":"Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.117165_bb0425","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1158\/2326-6066.CIR-21-0170","article-title":"Entinostat decreases immune suppression to promote antitumor responses in a HER2+ breast tumor microenvironment","volume":"10","author":"Sidiropoulos","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.intimp.2026.117165_bb0430","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/cdd.2009.150","article-title":"PI3K p110\u03b1 and p110\u03b2 have differential effects on Akt activation and protection against oxidative stress-induced apoptosis in myoblasts","volume":"17","author":"Matheny","year":"2009","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0435","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02072-1","article-title":"Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2026.117165_bb0440","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1189\/jlb.0809585","article-title":"The catalytic PI3K isoforms p110\u03b3 and p110\u03b4 contribute to B cell development and maintenance, transformation, and proliferation","volume":"87","author":"Beer-Hammer","year":"2010","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2026.117165_bb0445","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.718621","article-title":"Strategies to overcome failures in T-cell immunotherapies by targeting PI3K-\u03b4 and \u2013\u03b3","volume":"12","author":"Chandrasekaran","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.117165_bb0450","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/13543784.2017.1312338","article-title":"Duvelisib: a phosphoinositide-3 kinase \u03b4\/\u03b3 inhibitor for chronic lymphocytic leukemia","volume":"26","author":"Vangapandu","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"9","key":"10.1016\/j.intimp.2026.117165_bb0455","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/leu.2016.382","article-title":"Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)","volume":"31","author":"Patel","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.intimp.2026.117165_bb0460","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1158\/1078-0432.CCR-22-2386","article-title":"Duvelisib eliminates CLL B cells, impairs CLL-supporting cells, and overcomes ibrutinib resistance in a xenograft model","volume":"29","author":"Chen","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.intimp.2026.117165_bb0465","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/leu.2015.105","article-title":"The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (duvelisib), overcomes signals from the PI3K\/AKT\/S6 pathway and promotes apoptosis in CLL","volume":"29","author":"Balakrishnan","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.117165_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107126","article-title":"CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer","volume":"202","author":"Lv","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"18","key":"10.1016\/j.intimp.2026.117165_bb0475","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic Cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.117165_bb0480","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ccell.2017.10.005","article-title":"Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of Tumors","volume":"32","author":"Kumar","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.117165_bb0485","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2147\/DDDT.S253232","article-title":"<p>Pexidartinib, a novel small molecule CSF-1R inhibitor in use for tenosynovial giant cell tumor: a systematic review of pre-clinical and clinical development<\/p>","volume":"14","author":"Benner","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2026.117165_bb0490","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/17512433.2020.1771179","article-title":"Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors","volume":"13","author":"Baldi","year":"2020","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"29","key":"10.1016\/j.intimp.2026.117165_bb0495","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2217\/fon-2020-0542","article-title":"Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor","volume":"16","author":"Gelderblom","year":"2020","journal-title":"Future Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117165_bb0500","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/carcin\/bgac043","article-title":"CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model","volume":"43","author":"Omstead","year":"2022","journal-title":"Carcinogenesis"},{"issue":"7","key":"10.1016\/j.intimp.2026.117165_bb0505","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae345","article-title":"Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study","volume":"30","author":"Wagner","year":"2025","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.intimp.2026.117165_bb0510","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.33312","article-title":"Long-term outcomes of pexidartinib in tenosynovial giant cell tumors","volume":"127","author":"Gelderblom","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2026.117165_bb0515","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.722916","article-title":"CCL2: an important mediator between tumor cells and host cells in tumor microenvironment","volume":"11","author":"Jin","year":"2021","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117165_bb0520","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071882","article-title":"CCR2 of tumor microenvironmental cells is a relevant modulator of glioma biology","volume":"12","author":"Felsenstein","year":"2020","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.intimp.2026.117165_bb0525","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1038\/s41388-019-1141-7","article-title":"CCR2 signaling in breast carcinoma cells promotes tumor growth and invasion by promoting CCL2 and suppressing CD154 effects on the angiogenic and immune microenvironments","volume":"39","author":"Brummer","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2026.117165_bb0530","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.993444","article-title":"Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2+\/CX3CR1+ M-MDSCs into the tumor microenvironment in a redundant manner","volume":"13","author":"Takacs","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.117165_bb0535","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1158\/0008-5472.CAN-11-2493","article-title":"Tumor-derived chemokine CCL5 enhances TGF-\u03b2\u2013mediated killing of CD8+ T cells in Colon Cancer by T-regulatory cells","volume":"72","author":"Chang","year":"2012","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2026.117165_bb0540","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1158\/0008-5472.CAN-17-0915","article-title":"CCR5 governs DNA damage repair and breast Cancer stem cell expansion","volume":"78","author":"Jiao","year":"2018","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.intimp.2026.117165_bb0545","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1158\/0008-5472.CAN-19-1167","article-title":"Recent advances targeting CCR5 for Cancer and its role in immuno-oncology","volume":"79","author":"Jiao","year":"2019","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2026.117165_bb0550","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1021\/acsmedchemlett.1c00373","article-title":"BMS-813160: a potent CCR2 and CCR5 dual antagonist selected as a clinical candidate","volume":"12","author":"Cherney","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"issue":"17","key":"10.1016\/j.intimp.2026.117165_bb0555","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1158\/1078-0432.CCR-24-1821","article-title":"Neoadjuvant BMS-813160, nivolumab, gemcitabine, and nab-paclitaxel for patients with pancreatic Cancer","volume":"31","author":"Grierson","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117165_bb0560","doi-asserted-by":"crossref","first-page":"1623436","DOI":"10.3389\/fimmu.2025.1623436","article-title":"Targeting myeloid cells to improve cancer immune therapy","volume":"16","author":"Chen","year":"2025","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117165_bb0565","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11912-023-01361-0","article-title":"The development of STING agonists and emerging results as a Cancer immunotherapy","volume":"25","author":"Hines","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"12","key":"10.1016\/j.intimp.2026.117165_bb0570","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/j.apsb.2020.03.001","article-title":"Small molecules targeting the innate immune cGAS\u2013STING\u2013TBK1 signaling pathway","volume":"10","author":"Ding","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"14","key":"10.1016\/j.intimp.2026.117165_bb0575","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.7150\/thno.86792","article-title":"Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4+ T cells through regulating type 2 conventional dendritic cells","volume":"13","author":"Luo","year":"2023","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.intimp.2026.117165_bb0580","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112695","article-title":"STING agonists as cancer therapeutics","volume":"13","author":"Amouzegar","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.117165_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.116006","article-title":"Targeting ENPP1 for cancer immunotherapy: killing two birds with one stone","volume":"220","author":"Huang","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117165_bb0590","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061195","article-title":"Tam receptor inhibition\u2013implications for cancer and the immune system","volume":"13","author":"Aehnlich","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.intimp.2026.117165_bb0595","first-page":"801","article-title":"The CXCL12 (SDF-1)\/CXCR4 chemokine axis: oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy","volume":"16","author":"Zhou","year":"2018","journal-title":"Chin. J. Nat. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.117165_bb0600","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1535-7163.MCT-17-0643","article-title":"A role for CXCR4 in peritoneal and hematogenous ovarian Cancer dissemination","volume":"17","author":"Figueras","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.intimp.2026.117165_bb0605","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/s41375-024-02326-3","article-title":"CXCR4 as a therapeutic target in acute myeloid leukemia","volume":"38","author":"Korbecki","year":"2024","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.intimp.2026.117165_bb0610","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1517\/14712598.8.11.1797","article-title":"Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells","volume":"8","author":"Uy","year":"2008","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2026.117165_bb0615","first-page":"1141","article-title":"Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma: a systematic review and meta-analysis","author":"Yang","year":"2019","journal-title":"Exp. Ther. Med."},{"issue":"23","key":"10.1016\/j.intimp.2026.117165_bb0620","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0625","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of Cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr. Rev."},{"issue":"12","key":"10.1016\/j.intimp.2026.117165_bb0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0635","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41392-020-00347-9","article-title":"Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0640","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12935-021-01946-4","article-title":"Small molecule inhibitors against PD-1\/PD-L1 immune checkpoints and current methodologies for their development: a review","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"6","key":"10.1016\/j.intimp.2026.117165_bb0645","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.drudis.2016.04.011","article-title":"From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1\/PD-L1 pathway","volume":"21","author":"Zhan","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.intimp.2026.117165_bb0650","doi-asserted-by":"crossref","first-page":"1070961","DOI":"10.3389\/fimmu.2022.1070961","article-title":"PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117165_bb0655","article-title":"A small molecule antagonist of PD-1\/PD-L1 interactions acts as an immune checkpoint inhibitor for NSCLC and melanoma immunotherapy","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0660","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-020-0366-x","article-title":"Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway","volume":"42","author":"Wu","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.intimp.2026.117165_bb0665","doi-asserted-by":"crossref","first-page":"1444452","DOI":"10.3389\/fimmu.2024.1444452","article-title":"Small molecule inhibitors as adjuvants in cancer immunotherapy: enhancing efficacy and overcoming resistance","volume":"15","author":"Wu","year":"2024","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117165_bb0670","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.693","article-title":"BMS-202, a PD-1\/PD-L1 inhibitor, decelerates the pro-fibrotic effects of fibroblasts derived from scar tissues via ERK and TGF\u03b21\/Smad signaling pathways","volume":"10","author":"Cai","year":"2022","journal-title":"Immunity, Inflammation and Disease"},{"issue":"6","key":"10.1016\/j.intimp.2026.117165_bb0675","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.intimp.2026.117165_bb0680","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/2159-8290.CD-21-1156","article-title":"Characterization of INCB086550: a potent and novel small-molecule PD-L1 inhibitor","volume":"12","author":"Koblish","year":"2022","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.intimp.2026.117165_bb0685","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008547","article-title":"Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors","volume":"12","author":"Odegard","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0690","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s42003-021-02191-1","article-title":"PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy","volume":"4","author":"Sasikumar","year":"2021","journal-title":"Communications Biology."},{"issue":"15","key":"10.1016\/j.intimp.2026.117165_bb0695","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24152804","article-title":"CA-170 \u2013 a potent small-molecule PD-L1 inhibitor or not?","volume":"24","author":"Musielak","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.intimp.2026.117165_bb0700","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000683","article-title":"New emerging targets in cancer immunotherapy: the role of VISTA","volume":"4","author":"Tagliamento","year":"2019","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.intimp.2026.117165_bb0705","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1158\/2326-6066.CIR-18-0489","article-title":"Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell\u2013mediated inflammation and immunosuppression","volume":"7","author":"Xu","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2026.117165_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101308","article-title":"VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity","volume":"42","author":"ElTanbouly","year":"2019","journal-title":"Semin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0715","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-022-01292-5","article-title":"Bifunctional small molecules targeting PD-L1\/CXCL12 as dual immunotherapy for cancer treatment","volume":"8","author":"Cheng","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0720","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s13046-023-02900-0","article-title":"Cancer-associated fibroblasts-derived CXCL12 enhances immune escape of bladder cancer through inhibiting P62-mediated autophagic degradation of PDL1","volume":"42","author":"Zhang","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.117165_bb0725","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1053\/j.gastro.2013.07.025","article-title":"Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma","volume":"145","author":"Ene\u2013Obong","year":"2013","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.intimp.2026.117165_bb0730","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117165_bb0735","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12929-021-00737-3","article-title":"Roles of lysine-specific demethylase 1 (LSD1) in homeostasis and diseases","volume":"28","author":"Kim","year":"2021","journal-title":"J. Biomed. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2026.117165_bb0740","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.117165_bb0745","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.intimp.2026.117165_bb0750","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.intimp.2026.117165_bb0755","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1016\/j.celrep.2018.11.047","article-title":"Magnitude of therapeutic STING activation determines CD8(+) T cell-mediated anti-tumor immunity","volume":"25","author":"Sivick","year":"2018","journal-title":"Cell Rep."},{"issue":"6506","key":"10.1016\/j.intimp.2026.117165_bb0760","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1126\/science.abb4255","article-title":"Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic","volume":"369","author":"Chin","year":"2020","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.intimp.2026.117165_bb0765","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2026.117165_bb0770","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123837","article-title":"Targeting adenosine receptor Signaling in Cancer immunotherapy","volume":"19","author":"Sek","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2026.117165_bb0775","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117165_bb0780","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1172\/JCI86892","article-title":"The host STING pathway at the interface of cancer and immunity","volume":"126","author":"Corrales","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.intimp.2026.117165_bb0785","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926010118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926010118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:06:07Z","timestamp":1789142767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926010118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":157,"alternative-id":["S1567576926010118"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117165","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting antibody-inaccessible immune resistance with small-molecule immunotherapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117165"}}